Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis United States (53% of Non-Current Assets) by Year
United States (53% of Non-Current Assets) ($M)
Novartis United States (53% of Non-Current Assets): $36,272M in FY2025, up 3.6% from a year earlier.
Latest, FY2025
36,272
Period ended Dec 31, 2025
Change on a year earlier
+3.6%
34,999 in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Novartis Form 20-F (0001114448-26-000004) ↗
Reported in Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | United States (53% of Non-Current Assets) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 36,272 | +3.6% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2024 | Dec 31, 2024 | 34,999 | +2.8% | Novartis Form 20-F (0001114448-26-000004) ↗ |
| FY2023 | Dec 31, 2023 | 34,059 | -3.7% | Novartis Form 20-F (0001370368-25-000004) ↗ |
| FY2022 | Dec 31, 2022 | 35,353 | -4.6% | Novartis Form 20-F (0001370368-24-000004) ↗ |
| FY2021 | Dec 31, 2021 | 37,054 | -7.1% | Novartis Form 20-F/A (0001370368-23-000048) ↗ |
| FY2020 | Dec 31, 2020 | 39,889 | +38.1% | Novartis Form 20-F (0001370368-22-000010) ↗ |
| FY2019 | Dec 31, 2019 | 28,893 | -26.1% | Novartis Form 20-F (0001370368-21-000006) ↗ |
| FY2018 | Dec 31, 2018 | 39,082 | +37.2% | Novartis Form 20-F (0001370368-20-000003) ↗ |
| FY2017 | Dec 31, 2017 | 28,476 | – | Novartis Form 20-F (0001370368-19-000002) ↗ |
Breakdown
What makes up united States (53% of Non-Current Assets)
Cite this data
StockData. (2026). Novartis United States (53% of Non-Current Assets) ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/geo-nca-us
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.